ASLAN Pharmaceuticals Limited (ASLN)
$0.6879
+0.01 (+1.16%)
Rating:
Recommendation:
-
| Symbol | ASLN |
|---|---|
| Price | $0.6879 |
| Beta | 1.631 |
| Volume Avg. | 0.22M |
| Market Cap | 47.977M |
| Shares () | - |
| 52 Week Range | 0.341-1.16 |
| 1y Target Est | - |
| DCF Unlevered | ASLN DCF -> | |
|---|---|---|
| DCF Levered | ASLN LDCF -> | |
| ROE | -76.67% | Strong Sell |
| ROA | -52.26% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 229.08% | Strong Buy |
| P/E | - | |
| P/B | 2.17 | Strong Buy |
Latest ASLN news
About
Download (Excel)Dr. Carl Alan Jason Morton Firth
Healthcare
Biotechnology
NASDAQ Global Market
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.